SEC Form 5 · accession 0001209191-17-009699
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Emil D Kakkis
Officer — President & CEO · Director
Period of report
Dec 31, 2016
Accepted (ET)
Feb 10, 2017 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 22, 2016 | G | 27,500 | $0.00 | D | 419,647 | D | |
| Common Stock | holding | — | — | — | 2,552,241 | I | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
Table II — derivative securities
No Table II lines on this filing.
Remarks
Exhibit List: Exhibit 24 - Limited Power of Attorney